Professor Jianchun Duan: Personalized Neoantigen DC Vaccine LK101 Plus Immunotherapy—Exploring a New First-Line Maintenance Strategy for NSCLC

Professor Jianchun Duan: Personalized Neoantigen DC Vaccine LK101 Plus Immunotherapy—Exploring a New First-Line Maintenance Strategy for NSCLC

Immunotherapy combined with chemotherapy has become the standard first-line treatment for driver gene-negative non-small cell lung cancer (NSCLC). However, owing to the heterogeneity of the tumor immune microenvironment and complex mechanisms of primary and acquired resistance, the efficacy of existing regimens has reached a plateau, with only limited improvements in patient survival. How to optimize first-line maintenance strategies and overcome treatment resistance has therefore become a key clinical challenge. Therapeutic cancer vaccines offer a promising approach to addressing this unmet need by stimulating specific antitumor immune responses.
ESMO Investigator Insights | Professor Tianqi Zhang: Exploring Aipaluolitovorelizumab Plus Interventional Therapy as a Later-Line Treatment Strategy for HCC Progressing After Targeted Therapy and Immunotherapy

ESMO Investigator Insights | Professor Tianqi Zhang: Exploring Aipaluolitovorelizumab Plus Interventional Therapy as a Later-Line Treatment Strategy for HCC Progressing After Targeted Therapy and Immunotherapy

What treatment options remain for patients with advanced hepatocellular carcinoma (HCC) whose disease progresses following targeted therapy combined with immunotherapy? At the 2026 European Society for Medical Oncology (ESMO) Congress, a retrospective study reported preliminary results of aipaluolitovorelizumab (hereafter referred to as the "combination antibody regimen") combined with arterial interventional therapy and bevacizumab. The study included 13 patients, with objective response rates (ORRs) of 38.46% and 46.15% according to RECIST 1.1 and mRECIST, respectively. Oncology Frontier interviewed Professor Tianqi Zhang of Sun Yat-sen University Cancer Center to discuss the treatment design, management of intrahepatic lesions, and future research directions.
CSCO 2026 | Professor Lang He: China’s First CSCO Cancer Pain Guidelines Released, Advancing Comprehensive Cancer Pain Management Nationwide

CSCO 2026 | Professor Lang He: China’s First CSCO Cancer Pain Guidelines Released, Advancing Comprehensive Cancer Pain Management Nationwide

During the 2026 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), the first-ever CSCO cancer pain guidelines, the CSCO Guidelines for the Diagnosis and Treatment of Cancer Pain, were officially released, providing clinicians with standardized guidance that integrates the latest advances with the characteristics of clinical practice in China. Cancer pain remains highly prevalent in China, while the quality of its management varies considerably across different levels of healthcare institutions. The release of these new guidelines therefore comes at a particularly important time.
ESMO Voices from China | Professor Anwen Xiong: First-in-Class PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009 — Structural Innovation to Overcome Treatment Challenges in Advanced NSCLC

ESMO Voices from China | Professor Anwen Xiong: First-in-Class PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009 — Structural Innovation to Overcome Treatment Challenges in Advanced NSCLC

In recent years, immunotherapy for advanced non-small cell lung cancer (NSCLC) has evolved from the era of programmed cell death protein 1 (PD-1) monoclonal antibodies into the era of Immunotherapy 2.0, represented by bispecific antibodies. However, improving the objective response rate (ORR) while maintaining a favorable safety profile remains a major unmet clinical challenge.
2026 IFSC | Professor Abdullah Khan: Human Bone Marrow Organoids—A Novel In Vitro Platform for Precision Development in Hematologic Malignancies

2026 IFSC | Professor Abdullah Khan: Human Bone Marrow Organoids—A Novel In Vitro Platform for Precision Development in Hematologic Malignancies

Basic stem cell research, regenerative medicine, cell therapy, and the clinical application of research guidelines are among the most closely watched frontiers in hematology and translational medicine worldwide. With these topics at its core, The 10th International Forum on Stem Cells (IFSC) brought together leading experts and scholars from around the world to explore scientific discoveries and technological innovations, showcase the latest advances in basic, clinical, and translational hematopoietic stem cell research, and promote collaborative innovation across the global stem cell field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Abdullah Khan to share his latest research findings and academic insights on “Human Bone Marrow Organoids: A New Experimental Platform for Precision Development in Hematologic Malignancies.” The key points are presented below for our readers.
2026 IFSC | Professor Ari Melnick: Epigenetic Mechanisms of Stem-Like Plasticity in B-Cell Lymphomas and Targeted Therapeutic Strategies

2026 IFSC | Professor Ari Melnick: Epigenetic Mechanisms of Stem-Like Plasticity in B-Cell Lymphomas and Targeted Therapeutic Strategies

Basic stem cell research, regenerative medicine, cell therapy, and the clinical application of research guidelines are among the most closely watched frontiers in hematology and translational medicine worldwide. With these topics at its core, The 10th International Forum on Stem Cells (IFSC) brought together leading experts and scholars from around the world to explore scientific discoveries and technological innovations, showcase the latest advances in basic, clinical, and translational hematopoietic stem cell research, and promote collaborative innovation across the global stem cell field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Ari Melnick, Director of the Josep Carreras Leukaemia Research Institute in Spain, to share his latest research findings and academic insights into the mechanisms underlying the acquisition of stem-like plasticity in B-cell lymphomas and emerging targeted therapeutic strategies. The key points are presented below for our readers.
ESMO Insights | Professor Barbara Pistilli: Updated VIKTORIA-1 Results Show Sustained Survival Benefit and Improved Safety with Gedatolisib-Based Combinations in PIK3CA-Mutant Advanced Breast Cancer

ESMO Insights | Professor Barbara Pistilli: Updated VIKTORIA-1 Results Show Sustained Survival Benefit and Improved Safety with Gedatolisib-Based Combinations in PIK3CA-Mutant Advanced Breast Cancer

At the 2026 ESMO Congress, Professor Barbara Pistilli of Gustave Roussy Cancer Center, France, presented updated results from VIKTORIA-1 Study 2 in patients with PIK3CA-mutant disease. The study showed that both the gedatolisib triplet combination (gedatolisib + palbociclib + fulvestrant) and the doublet combination (gedatolisib + fulvestrant) significantly improved progression-free survival (PFS) compared with alpelisib plus fulvestrant, regardless of whether patients had visceral or liver metastases. Based on these findings, Oncology Frontier interviewed Professor Barbara Pistilli at the congress to discuss the subgroup analyses, safety data, and clinical implications of the study.
ESMO Insights | Professor Gustavo Werutsky: lidERA BC PRO Results Show Giredestrant Improves Efficacy While Preserving Quality of Life

ESMO Insights | Professor Gustavo Werutsky: lidERA BC PRO Results Show Giredestrant Improves Efficacy While Preserving Quality of Life

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27 (local time). At the meeting, Professor Gustavo Werutsky of Moinhos de Vento Hospital in Porto Alegre, Brazil, presented patient-reported outcome (PRO) data from the phase III lidERA BC study (Abstract No. 538RO). The study evaluated the efficacy and safety of giredestrant, an oral selective estrogen receptor degrader (SERD), as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative (ER+/HER2−) early breast cancer. The PRO analysis showed that, alongside a significant improvement in invasive disease-free survival (iDFS), giredestrant effectively preserved patients' health-related quality of life (HRQoL) and daily functioning, while significantly reducing the burden of side effects and the risk of treatment discontinuation. Following his presentation, Oncology Frontier invited Professor Gustavo Werutsky for an interview to discuss the key findings and clinical implications of the lidERA BC PRO data, as well as their potential impact on the future landscape of adjuvant endocrine therapy.
ESMO Insights | Professor Hope S. Rugo: KEYNOTE-B49 Shows PFS Benefit with Immunotherapy Plus Chemotherapy in HR+/HER2− Advanced Breast Cancer

ESMO Insights | Professor Hope S. Rugo: KEYNOTE-B49 Shows PFS Benefit with Immunotherapy Plus Chemotherapy in HR+/HER2− Advanced Breast Cancer

At the 2026 ESMO Congress, Professor Hope S. Rugo of City of Hope Comprehensive Cancer Center, California, USA, presented the interim analysis (IA) and final analysis (FA) results of the KEYNOTE-B49 study. The findings showed that pembrolizumab plus chemotherapy significantly improved progression-free survival (PFS) in patients with PD-L1 CPS ≥1, HR-positive/HER2-negative advanced breast cancer (ABC). The PFS benefit was more pronounced in the subgroup with PD-L1 CPS ≥10. In addition, the immunotherapy combination more than tripled the 24-month PFS rate, with an overall manageable safety profile. These findings suggest that some patients with endocrine-resistant and more aggressive disease may benefit from immunotherapy. Oncology Frontier interviewed Professor Hope S. Rugo at the ESMO Congress to discuss the key findings from KEYNOTE-B49, the clinical benefits observed in specific subgroups, and the role of PD-L1 testing in guiding clinical practice.